Stay updated with breaking news from Nasdaq Dcph. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Deciphera Pharmaceuticals (NASDAQ:DCPH – Get Free Report) had its target price increased by Stifel Nicolaus from $20.00 to $22.00 in a report issued on Tuesday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Stifel Nicolaus’ target price would indicate a potential upside of 88.68% from the company’s current price. DCPH has […]
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH – Get Free Report) CEO Steven L. Hoerter sold 21,573 shares of the stock in a transaction on Monday, October 30th. The stock was sold at an average price of $12.02, for a total value of $259,307.46. Following the sale, the chief executive officer now owns 40,927 shares in the company, […]
Shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH – Get Free Report) hit a new 52-week low on Wednesday . The stock traded as low as $10.24 and last traded at $10.55, with a volume of 14011 shares changing hands. The stock had previously closed at $10.57. Analyst Ratings Changes DCPH has been the subject of a […]
Shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the eight ratings firms that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating […]
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the nine research firms that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and seven have assigned a buy recommendation to the […]